GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Beneish M-Score

Renalytix (Renalytix) Beneish M-Score : 2.18 (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Renalytix Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 2.18 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Renalytix's Beneish M-Score or its related term are showing as below:

RNLX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.55   Med: -2.81   Max: 2.18
Current: 2.18

During the past 6 years, the highest Beneish M-Score of Renalytix was 2.18. The lowest was -4.55. And the median was -2.81.


Renalytix Beneish M-Score Historical Data

The historical data trend for Renalytix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Beneish M-Score Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial - - - -2.81 -4.55

Renalytix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.00 -2.60 -4.55 -3.96 2.18

Competitive Comparison of Renalytix's Beneish M-Score

For the Health Information Services subindustry, Renalytix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Renalytix's Beneish M-Score falls into.



Renalytix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Renalytix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.3582+0.528 * 3.5901+0.404 * 10.5952+0.892 * 0.6335+0.115 * 0.8255
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9488+4.679 * -0.290025-0.327 * 1.2364
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $1.37 Mil.
Revenue was 0.709 + 0.459 + 0.518 + 0.724 = $2.41 Mil.
Gross Profit was 0.257 + -0.043 + -0.155 + 0.121 = $0.18 Mil.
Total Current Assets was $9.47 Mil.
Total Assets was $21.87 Mil.
Property, Plant and Equipment(Net PPE) was $0.68 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.55 Mil.
Selling, General, & Admin. Expense(SGA) was $21.87 Mil.
Total Current Liabilities was $13.90 Mil.
Long-Term Debt & Capital Lease Obligation was $5.31 Mil.
Net Income was -9.132 + -10.154 + -11.104 + -12.106 = $-42.50 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -7.843 + -9.504 + -8.633 + -10.172 = $-36.15 Mil.
Total Receivables was $0.92 Mil.
Revenue was 1.192 + 0.969 + 0.831 + 0.812 = $3.80 Mil.
Gross Profit was 0.481 + 0.273 + 0.139 + 0.127 = $1.02 Mil.
Total Current Assets was $26.60 Mil.
Total Assets was $30.66 Mil.
Property, Plant and Equipment(Net PPE) was $2.51 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.47 Mil.
Selling, General, & Admin. Expense(SGA) was $36.38 Mil.
Total Current Liabilities was $14.29 Mil.
Long-Term Debt & Capital Lease Obligation was $7.49 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.37 / 2.41) / (0.917 / 3.804)
=0.568465 / 0.241062
=2.3582

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.02 / 3.804) / (0.18 / 2.41)
=0.268139 / 0.074689
=3.5901

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9.467 + 0.683) / 21.874) / (1 - (26.601 + 2.508) / 30.66)
=0.535979 / 0.050587
=10.5952

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.41 / 3.804
=0.6335

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.471 / (1.471 + 2.508)) / (0.554 / (0.554 + 0.683))
=0.369691 / 0.447858
=0.8255

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(21.868 / 2.41) / (36.381 / 3.804)
=9.073859 / 9.56388
=0.9488

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.31 + 13.897) / 21.874) / ((7.488 + 14.287) / 30.66)
=0.878074 / 0.710209
=1.2364

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-42.496 - 0 - -36.152) / 21.874
=-0.290025

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Renalytix has a M-score of 2.24 signals that the company is likely to be a manipulator.


Renalytix Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Renalytix's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Executives
Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE